Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell purging ex vivo

M V Seiden1, K C Anderson

  • 1Division of Hematology and Oncology, Massachusetts General Hospital, Boston, USA.

The Journal of Infusional Chemotherapy
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

mAbs·2025
Same author

Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.

Leukemia·2024
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same journal

Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma.

The Journal of infusional chemotherapy·1996
Same journal

Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.

The Journal of infusional chemotherapy·1996
Same journal

The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.

The Journal of infusional chemotherapy·1996
Same journal

The French experience with infusional 5-FU in gastric and pancreatic cancer.

The Journal of infusional chemotherapy·1996
Same journal

Drug stability and compatibility in oncology care.

The Journal of infusional chemotherapy·1996
Same journal

Options for venous access in ambulatory care: issues in selection and management.

The Journal of infusional chemotherapy·1996
See all related articles

Detecting tumor cells in bone marrow (BM) and peripheral blood progenitor cells (PBPC) has advanced significantly. While techniques confirm frequent contamination, the clinical benefit of purging these cells requires further study in trials.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Diagnostics

Background:

  • Bone marrow (BM) and peripheral blood progenitor cells (PBPC) are frequently contaminated with tumor cells.
  • Tumor cell contamination poses a risk for disease relapse after autograft procedures.

Purpose of the Study:

  • To review techniques for detecting tumor cell contamination in BM and PBPC.
  • To evaluate the effectiveness of ex vivo processing strategies for reducing tumor cell contamination.
  • To discuss the clinical implications of residual tumor cells in autografts.

Main Methods:

  • Immunohistochemistry
  • In situ hybridization (ISH)
  • Flow cytometry
  • Clonogenic tumor assays

Related Experiment Videos

  • Polymerase chain reaction (PCR)-based assays
  • Gene marking studies

    • Main Results:

    • Detection capabilities vary widely, from 1 tumor cell in 100 to 1 tumor cell in a million.
    • BM contamination is generally higher than in PBPC.
    • Gene marking studies confirm tumor cell viability and potential for relapse.
    • Purging techniques can reduce tumor contamination by 3-5 logs; positive selection by 3-4 logs.

    Conclusions:

    • Advanced techniques effectively detect tumor cell contamination in BM and PBPC.
    • Ex vivo processing can significantly reduce tumor cell load.
    • The clinical benefit of purging and its impact on patient outcomes require validation through randomized clinical trials.